Novartis Contracts with Cryoport to Support Novartis Cell Therapies

Jul 25, 2017
By Applied Clinical Trials Editors

Novartis has signed an aggreement contracting Cryoport—provider of logistics solutions for biopharmaceutical, IVF, and animal health organizations globally—over an initial three-year tern for cryogenic logistics support of CTL019/CD19 CAR-T cell therapy.

Read the full release here.

 

 

native1_300x100
lorem ipsum